The Trump administration announced its newest pharmaceutical agreement under its Most Favored Nation policy Thursday, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices.

According to senior administration officials, the two manufacturers have agreed to sell their injectable GLP-1 products for a monthly starting price starting of $245 for people on Medicare and Medicaid, as well as those who use the TrumpRX platform expected to launch early next year.

Oral GLP-1s will also be sold through the same avenues at a starting price of $149 per month. A senior administration official said, however, that this price will only apply to GLP-1 tablets that are “currently under review that will be approved for obesity” and will not apply to Rybelsus, which

See Full Page